The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma

MLA

Fei-Xiang Wu, et al. “The Safety and Efficacy of Transarterial Chemoembolization Combined with Sorafenib and Sorafenib Mono-Therapy in Patients with BCLC Stage B/C Hepatocellular Carcinoma.” BMC Cancer, vol. 17, no. 1, Sept. 2017, pp. 1–11. EBSCOhost, https://doi.org/10.1186/s12885-017-3545-5.

APA

Fei-Xiang Wu, Jie Chen, Tao Bai, Shao-Liang Zhu, Tian-Bo Yang, Lu-Nan Qi, Ling Zou, Zi-Hui Li, Jia-Zhou Ye, & Le-Qun Li. (2017). The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma. BMC Cancer, 17(1), 1–11. https://doi.org/10.1186/s12885-017-3545-5

Chicago

Fei-Xiang Wu, Jie Chen, Tao Bai, Shao-Liang Zhu, Tian-Bo Yang, Lu-Nan Qi, Ling Zou, Zi-Hui Li, Jia-Zhou Ye, and Le-Qun Li. 2017. “The Safety and Efficacy of Transarterial Chemoembolization Combined with Sorafenib and Sorafenib Mono-Therapy in Patients with BCLC Stage B/C Hepatocellular Carcinoma.” BMC Cancer 17 (1): 1–11. doi:10.1186/s12885-017-3545-5.